scholarly journals Adeno-Associated Virus Serotype 9–Driven Expression of BAG3 Improves Left Ventricular Function in Murine Hearts With Left Ventricular Dysfunction Secondary to a Myocardial Infarction

2016 ◽  
Vol 1 (7) ◽  
pp. 647-656 ◽  
Author(s):  
Tijana Knezevic ◽  
Valerie D. Myers ◽  
Feifei Su ◽  
JuFang Wang ◽  
Jianliang Song ◽  
...  
2018 ◽  
Author(s):  
Kawa Haji ◽  
Joshua Wong ◽  
Chiew Wong ◽  
Koen Simons ◽  
Nicholas Cox ◽  
...  

BACKGROUND Evidence suggests long term benefit from angiotensin converting enzyme inhibition (ACE-I) or angiotensin receptor blockade (ARB), beta-adrenoceptor antagonism and mineralocorticoid antagonism (MRA) in patients with left ventricular dysfunction After myocardial infarction. However, despite clinical evidence and clearly articulated guidelines, several studies suggest low rates of prescription of some medications like MRA in the target group with post- myocardial infarction left ventricular dysfunction (MI LVD), both in Australia and other countries OBJECTIVE To identify the real world medication prescription in ST elevation myocardial infarction (STEMI) patients with impaired left ventricular function METHODS We studied prescription trends in 152 consecutive STEMI patients between August 2013 and December 2016 admitted to a single referral centre who also had a pre-discharge echo that demonstrated at least moderate Left ventricular dysfunction RESULTS The average age was 63 years. Most patients were male (78%) and the average BMI was 28 (±6). 132 patients [87% (80% - 92%)] were prescribed ACE-I/ARBs, 144 patients received beta-adrenoceptor antagonists (95% [90% - 98%]), 147 patients (97%) received DAPT and 146 patients (95%) received statins post-STEMI. 45 eligible patients (30% [23% - 28%]) received an MRA. Younger patients were more likely to be prescribed an MRA (p = 0.008). The MRA prescribed cohort were younger, 59 versus 64 years, had marginally better renal function with average eGFR 108 vs 91 mL/min/1.73m2 and lower rates of stage ≥III CKD 11 vs 22 (p <0.05) CONCLUSIONS Our study shows a substantial treatment gap, in that a majority of patients with impaired LV dysfunction after STEMI with symptoms of heart failure or diabetes are not receiving medications in the MRA class, despite proven benefit. As such, the root causes of this treatment gap require elucidation in a multi-centre context.


2004 ◽  
Vol 29 (2) ◽  
pp. 117-118 ◽  
Author(s):  
Mauro Feola ◽  
Alberto Biggi ◽  
Antonella Francini ◽  
Giovanni Leonardi ◽  
Flavio Ribichini ◽  
...  

2013 ◽  
Vol 24 (9) ◽  
pp. 777-785 ◽  
Author(s):  
Mei Hua Gao ◽  
N. Chin Lai ◽  
Atsushi Miyanohara ◽  
Jan M. Schilling ◽  
Jorge Suarez ◽  
...  

2017 ◽  
Vol 11 (4) ◽  
pp. NP103-NP106 ◽  
Author(s):  
Lloyd M. Felmly ◽  
Andrew J. Savage ◽  
Minoo N. Kavarana

Small infants with severe left ventricular dysfunction (LVD) carry a poor prognosis with limited therapeutic options. Although mechanical support and heart transplantation are definitive therapies, improvement of left ventricular function with reversible pulmonary artery banding (rPAB) has been described. We report two cases of LVD treated with rPAB. One was successfully temporized, and one progressed to requiring transplantation, indicating that appropriate patient selection is critical to this technique's success.


Sign in / Sign up

Export Citation Format

Share Document